Wyatt Calypso Succeeds in ABRF-MIRG Study
News Apr 29, 2013
The conclusions of the 2012 MIRG study were announced at the ABRF 2013 annual meeting in Palm Springs earlier this month.
In the study, a pair of unknown proteins, prepared and characterized by the ABRF, was sent out to multiple labs to determine affinity and stoichiometry of binding. In a single afternoon consisting of 2 CG-MALS runs, the Wyatt Calypso system correctly determined that one molecule of Protein Y (26.3 kDa) binds 2 molecules of Protein X (11.9 kDa), one with KD of 10 nM and the other with 14 µM. This analysis agreed perfectly with the extensive AUC and ITC measurements performed by ABRF prior to distributing the samples.
The CG-MALS measurement was the only solution-based measurement among the participating labs. The others used surface plasmon resonance (SPR) instruments which require immobilization of one of the binding partners. Only 4 of 13 SPR labs correctly measured and interpreted the data, typically taking 1-2 days even though the chip immobilization recipe and regeneration were provided by the organizers.
Interestingly, the affinities determined by SPR were significantly weaker than those found by any of the solution-based measurements (AUC, ITC, CG-MALS), indicating that, in this instance, immobilization modifies the interaction.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE